195 related articles for article (PubMed ID: 20081809)
21. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of CD133 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Mitsui H; Yazawa T; Ogawa N; Tajiri M; Yamamoto T; Rino Y; Kitamura H; Masuda M
Int J Clin Exp Pathol; 2010 Dec; 4(1):32-42. PubMed ID: 21228926
[TBL] [Abstract][Full Text] [Related]
23. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
25. CD133 expression associated with poor prognosis in ovarian cancer.
Zhang J; Guo X; Chang DY; Rosen DG; Mercado-Uribe I; Liu J
Mod Pathol; 2012 Mar; 25(3):456-64. PubMed ID: 22080056
[TBL] [Abstract][Full Text] [Related]
26. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
27. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
28. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
Li XF; Guo XG; Yang YY; Liu AY
Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
30. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
34. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
35. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study.
Kojima M; Ishii G; Atsumi N; Fujii S; Saito N; Ochiai A
Cancer Sci; 2008 Aug; 99(8):1578-83. PubMed ID: 18754869
[TBL] [Abstract][Full Text] [Related]
37. Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.
Li H; Zhao P; Lu Y; Lu Y
Int J Colorectal Dis; 2012 Aug; 27(8):1015-20. PubMed ID: 22315171
[TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
39. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
